Common and Drug-Specific Toxicities of Datopotamab Deruxtecan
The answer is D - all of the above: stomatitis, dry eye, and nausea are all common toxicities associated with datopotamab deruxtecan, with stomatitis being the most characteristic and frequently reported adverse event.
Most Prominent Toxicity: Stomatitis/Oral Mucositis
Stomatitis represents the signature toxicity of datopotamab deruxtecan and occurs with notably high frequency compared to standard chemotherapy. In the TROPION-Breast01 trial, stomatitis was the most commonly reported adverse reaction (≥20% of patients) 1. The FDA label specifically highlights stomatitis as a key adverse reaction 2. In the TROPION-Lung05 study of heavily pretreated NSCLC patients, stomatitis occurred in 56.2% of patients (any grade) with 9.5% experiencing grade ≥3 events 3.
This toxicity is sufficiently important that it has been designated as an adverse event of special interest (AESI) requiring specific prophylaxis, monitoring, and management protocols 4.
Ocular Toxicity: Dry Eye and Keratitis
Dry eye is a distinctive toxicity of datopotamab deruxtecan that differentiates it from conventional chemotherapy. The FDA label lists both dry eye and keratitis among the most common adverse reactions (≥20%) 1. Ocular surface events have been identified as AESIs requiring:
- Proactive ophthalmologic consultation
- Regular monitoring
- Early intervention strategies 4
This represents a drug-specific toxicity pattern not typically seen with standard chemotherapy comparators like docetaxel.
Gastrointestinal Toxicity: Nausea
Nausea is consistently reported as a common adverse event with datopotamab deruxtecan. The FDA label identifies nausea as occurring in ≥20% of patients 1. In the TROPION-Lung01 trial comparing datopotamab deruxtecan to docetaxel, nausea was among the most frequently reported adverse events 5.
Additional Common Toxicities
Beyond the three options listed, datopotamab deruxtecan is also associated with:
- Fatigue (very common, ≥20%)
- Alopecia (≥20%)
- Constipation (≥20%)
- Vomiting (≥20%)
Critical Safety Consideration: Interstitial Lung Disease
While not listed in the answer options, interstitial lung disease/pneumonitis represents the most serious toxicity requiring vigilant monitoring. In TROPION-Lung01, ILD occurred in 8.8% of datopotamab deruxtecan patients versus 4.1% with docetaxel 5. This is a class effect of deruxtecan-containing ADCs and requires immediate dose interruption and corticosteroid treatment 4.
Favorable Hematologic Profile
Importantly, datopotamab deruxtecan demonstrates significantly less hematologic toxicity than standard chemotherapy, which represents a major clinical advantage. Grade ≥3 treatment-related adverse events occurred in only 25.6% with datopotamab deruxtecan versus 42.1% with docetaxel 5. This lower rate of severe toxicity contributes to improved quality of life despite the unique toxicity profile.
Clinical Pitfall
The combination of stomatitis, ocular events, and gastrointestinal symptoms requires multidisciplinary management involving oncology, ophthalmology, and supportive care specialists. Failure to implement prophylactic measures (particularly for stomatitis) and early intervention can lead to dose reductions or discontinuation, potentially compromising efficacy 6, 4.